Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date

Álvaro Machado,1 Tiago Torres1,2 1Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal; 2Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal Abstract: Psoriasis is a common chronic immune-media...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Machado Á, Torres T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	psoriasis IL-23 risankizumab Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/0024f89d204e4d6f81ccd0f66c542e61
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0024f89d204e4d6f81ccd0f66c542e61
record_format	dspace
spelling	oai:doaj.org-article:0024f89d204e4d6f81ccd0f66c542e612021-12-02T00:02:26ZSpotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date2230-326Xhttps://doaj.org/article/0024f89d204e4d6f81ccd0f66c542e612018-11-01T00:00:00Zhttps://www.dovepress.com/spotlight-on-risankizumab-and-its-potential-in-the-treatment-of-plaque-peer-reviewed-article-PTThttps://doaj.org/toc/2230-326XÁlvaro Machado,1 Tiago Torres1,2 1Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal; 2Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal Abstract: Psoriasis is a common chronic immune-mediated skin disease, with systemic involvement and significant impact in patients’ quality of life. Several highly specific treatments have been developed over the years, such as tumor necrosis factor-α inhibitors, a nonselective IL-23 inhibitor (ustekinumab), and most recently IL-17 inhibitors. Risankizumab is a monoclonal antibody which targets IL-23p19 without binding IL-12. This novel therapeutic approach is expected to have advantages over the recently approved anti-IL-17 agents, such as the avoidance of Candida infections and neutropenia. In addition, unlike ustekinumab, the selective inhibition of IL-23 may preserve IL-12-dependent functions such as protection against infections and tumor immune surveillance. Risankizumab showed an excellent efficacy when compared to placebo and ustekinumab, with higher Psoriasis Area Severity Index (PASI) 75, PASI 90, and PASI 100 rates, along with a convenient every 12-week maintenance dosing regimen. Overall, risankizumab was well tolerated and the most common adverse event was upper respiratory tract infection. In the near future, further data will be available not only in psoriasis but also in Crohn’s disease and psoriatic arthritis fields. Head-to-head trials comparing risankizumab with other IL-23 inhibitors and with IL-17 inhibitors will be crucial to reveal the role of risankizumab in the treatment of psoriasis. Keywords: psoriasis, IL-23, risankizumabMachado ÁTorres TDove Medical PressarticlepsoriasisIL-23risankizumabDermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol Volume 8, Pp 83-92 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	psoriasis IL-23 risankizumab Dermatology RL1-803
spellingShingle	psoriasis IL-23 risankizumab Dermatology RL1-803 Machado Á Torres T Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
description	Álvaro Machado,1 Tiago Torres1,2 1Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal; 2Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal Abstract: Psoriasis is a common chronic immune-mediated skin disease, with systemic involvement and significant impact in patients’ quality of life. Several highly specific treatments have been developed over the years, such as tumor necrosis factor-α inhibitors, a nonselective IL-23 inhibitor (ustekinumab), and most recently IL-17 inhibitors. Risankizumab is a monoclonal antibody which targets IL-23p19 without binding IL-12. This novel therapeutic approach is expected to have advantages over the recently approved anti-IL-17 agents, such as the avoidance of Candida infections and neutropenia. In addition, unlike ustekinumab, the selective inhibition of IL-23 may preserve IL-12-dependent functions such as protection against infections and tumor immune surveillance. Risankizumab showed an excellent efficacy when compared to placebo and ustekinumab, with higher Psoriasis Area Severity Index (PASI) 75, PASI 90, and PASI 100 rates, along with a convenient every 12-week maintenance dosing regimen. Overall, risankizumab was well tolerated and the most common adverse event was upper respiratory tract infection. In the near future, further data will be available not only in psoriasis but also in Crohn’s disease and psoriatic arthritis fields. Head-to-head trials comparing risankizumab with other IL-23 inhibitors and with IL-17 inhibitors will be crucial to reveal the role of risankizumab in the treatment of psoriasis. Keywords: psoriasis, IL-23, risankizumab
format	article
author	Machado Á Torres T
author_facet	Machado Á Torres T
author_sort	Machado Á
title	Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
title_short	Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
title_full	Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
title_fullStr	Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
title_full_unstemmed	Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
title_sort	spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/0024f89d204e4d6f81ccd0f66c542e61
work_keys_str_mv	AT machadoa spotlightonrisankizumabanditspotentialinthetreatmentofplaquepsoriasisevidencetodate AT torrest spotlightonrisankizumabanditspotentialinthetreatmentofplaquepsoriasisevidencetodate
_version_	1718403962362658816

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date

Ejemplares similares